EW Healthcare Partners
27.2.2024 21:03:28 CET | ACCESS Newswire | Press release
ORMOND BEACH, FL / ACCESSWIRE / February 27, 2024 / Germfree announces the appointments of Dorothy Puhy, Karen Flynn, Kerry Ingalls and Helga Salling as independent non-executive members of its Board of Directors.
"We are excited to welcome Dorothy, Karen, Kerry and Helga to our Board of Directors. Their counsel will guide strategic alternatives, aid Germfree in capitalizing on opportunities, and navigate future challenges. Leveraging their collective expertise, the Board will play a pivotal role in driving sustainable growth and ensuring long-term success. Germfree's story is one of relentless innovation, unwavering commitment to quality, and profound impact on global health. We remain committed to advancing innovation and maintaining our position as a leader in critical environment equipment, cleanrooms, and laboratories. Our Board will help Germfree to capitalize on emerging trends and technological advancements, particularly in the rapidly evolving fields of cell and gene therapy," said Kevin Kyle, CEO at Germfree.
Dorothy Puhy brings considerable experience to the Germfree Board and is well-recognized for her financial expertise. She dedicated 25 years to the Dana Farber Cancer Institute, culminating in her role as Executive Vice President and Chief Operating Officer. Prior to that, she was Chief Financial Officer and held various financial positions at the Tufts - New England Medical Center Hospitals. Dorothy served as a Lead Director at Abiomed for c. 20 years, until the successful acquisition of the company by JNJ. As a Lead Director of Abiomed, Dorothy worked closely with the management team and other Board members to set strategic goals and overall direction. In addition to Abiomed, Dorothy served on the boards of BCBS, Azenta and Reebok. She was on the adjunct faculty at Harvard School of Public Health for many years.
Karen Flynn brings more than three decades of commercial and operations experience to the board of Germfree. Most recently, she served as Interim President of BioModalities at Catalent. Preceding this role, Karen held positions as Chief Commercial Officer and President of Biologics at Catalent. Prior to her tenure at Catalent, she served as Senior Vice President and Chief Commercial Officer for West Pharmaceutical Services, also assuming the role of President of its Pharmaceutical Packaging Systems business. Besides her involvement with Germfree's board, Karen currently holds positions on the Boards of Quanterix Corporation and Sotera Health.
Kerry Ingalls is a pharma veteran who brings experience across manufacturing and operations. He previously served as Chief Operating Officer of Poseida Therapeutics, overseeing corporate strategic planning, operations, and the construction, commissioning, and licensing of the CGT manufacturing plant. Prior to his time at Poseida, Kerry held various leadership positions at Amgen for many years, managing multiple operations sites and overseeing all clinical and commercial GMP manufacturing at Amgen's global headquarters. Before joining Amgen, Kerry had a distinguished career in the US Navy.
Helga Salling presently holds the position of Vice President, Global Growth & Strategy- Life Sciences at Jacobs. With over 20 years of experience in the Life Sciences sector, Helga brings valuable expertise to the Germfree Board. Before joining Jacobs, Helga served as VP Integrated Projects at IPS, and before that, she held positions at DPS Group and served as COO at Advent Engineering.
"We are excited to welcome Dorothy, Karen, Kerry and Helga to our Board of Directors. They bring decades of experience, leadership and strategic thinking in key markets that Germfree serves. We are thrilled to be working with them as we aggressively scale the business to meet the needs of our customers, in particular in the cell and gene therapy space," said Evis Hursever, Managing Director at EW Healthcare Partners and Chair of the Board of Directors.
About Germfree
Germfree has become a globally recognized authority in cutting-edge critical environment equipment, cleanrooms, and laboratories for over six decades. The company has consistently led the way in pioneering cleanroom design and manufacturing, serving the biopharmaceutical, healthcare, and research sectors. Germfree remains resolutely committed to providing innovative solutions that significantly improve patient access to life-changing therapies.
About EW Healthcare Partners
With over $2 billion of capital raised since 2014, EW Healthcare Partners seeks to make growth equity investments in fast-growing commercial-stage healthcare companies in the pharmaceutical, medical device, diagnostics, and technology-enabled services sectors in the United States and in Europe. EW Healthcare Partners has a singular commitment to the healthcare industry and has been a long-term investor in numerous healthcare companies, ranging across sectors, stages and geographies. The team of senior investment professionals, operating partners and advisors is based in New York, London and Houston. https://www.ewhealthcare.com/
Media Contact
Lauren Blum, Content Marketing Manager at Germfree
+1 386-265-4300
Marketing@germfree.com
www.germfree.com
Contact Information
Lauren Blum
Content Marketing Manager
lblum@germfree.com
+1 386-265-4300
SOURCE: Germfree
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
New GTDC Research Illuminates Distribution's Expanding Role in Modern Technology Ecosystems29.7.2026 15:00:00 CEST | Press release
TAMPA, FL / ACCESS Newswire / July 29, 2026 / The Global Technology Distribution Council (GTDC), the world's largest consortium of technology distributors, today released a new research report, The Evolving Role of Distribution in Technology Go-To-Market Models, developed in partnership with Channelnomics. The study examines the shift in distribution from a traditional channel intermediary into a strategic operating platform that helps vendors and partners scale, increase support and overcome the complexities associated with innovation (i.e., AI and cybersecurity) and integration. According to the research, customer expectations are rising rapidly as organizations seek integrated outcomes across AI, cybersecurity, hybrid cloud, automation, analytics and managed services. Vendors and partners increasingly struggle to meet those market demands independently with solutions requiring cross-platform integration, multi-vendor coordination, lifecycle support and operational consistency. The G
TIS, EuroFinance Study Finds Corporate Treasurers Actively Evaluating AI, But Hesitant to Adopt It28.7.2026 15:00:00 CEST | Press release
The EuroFinance Deep Dive, supported by Treasury Intelligence Solutions (TIS), interviewed and surveyed corporate treasury leaders, finding that while they see AI as a powerful tool for cash forecasting, multiple concerns are deterring them from adopting it - for now. BERLIN, DE / ACCESS Newswire / July 28, 2026 / Treasury Intelligence Solutions (TIS), a best-in-class solution for payments and cash management, partnered with the research and trade association EuroFinance, in a research initiative that discovered nearly half of leading corporate finance teams are considering the use of artificial intelligence in cash forecasting - but just as many are holding off because of concerns over the technology. The EuroFinance Deep Dive, AI in Treasury: Accuracy, Intelligence and the Future of Cash Forecasting, brings together proprietary research, survey data, and perspectives from treasury leaders at Microsoft, Siemens Energy and other companies to assess where AI is creating value and where
CHAR Tech Provide Update on GazoTech's Bio-Methane Provence Project28.7.2026 14:00:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / July 28, 2026 / (TSXV:YES)(OTC PINK:CTRNF)(FSE:68K) GazoTech's lead project, Bio-Méthane Provence ("BMP"), an industrial-scale HTP project in France developed under the CHAR Tech / GazoTech collaboration, has successfully concluded its CNDP-supervised voluntary public consultation, with a clear majority of opinions supporting the project BMP is redeveloping the site of a former 600 MW coal-fired power plant in Gardanne, France, converting legacy fossil infrastructure into renewable energy production Once operational, BMP is expected to process 115,000 tonnes of recovered wood annually, producing 230 GWh (828,000 GJ) of RNG plus 12,000 tonnes of biocarbon, targeting commercial operations in H2 2029 CHAR Technologies Ltd. ("CHAR Tech" or "the Company"), a leader in sustainable biomass energy solutions, today provided an update on the Bio-Méthane Provence ("BMP") project in Gardanne, France, an industrial-scale High-Temperature Pyrolysis ("HTP") project bei
Giatec Completes Its First International MixPilot Fleet Roll-Out with Heidelberg Materials UK28.7.2026 11:00:00 CEST | Press release
Following a successful trial validating MixPilot in a new market, across an expanded range of truck types and slump measurement standards, Giatec and Heidelberg Materials sign a binding agreement to scale MixPilot across the Heidelberg Materials UK fleet. OTTAWA, ON / ACCESS Newswire / July 28, 2026 / Giatec, a global leader in digital concrete technology platforms, today announced that Giatec and Heidelberg Materials, one of the world's largest integrated manufacturers of heavy building materials and solutions, have scaled MixPilot across Heidelberg Materials' UK concrete operations. MixPilot was selected on the strength of two factors: superior slump accuracy, validated against other systems under real operating conditions, and driver adoption, with the superior app interface becoming a key catalyst for fleet-wide buy-in. "MixPilot delivered something simple but rare: data our team could trust from day one," said Fabrice Arriordaz, Regional Operations Manager, North Concrete, Heidelb
LiberNovo Omni SE, Omni Pro and Maxis Enter Final Week of Early Bird Launch Pricing24.7.2026 09:00:00 CEST | Press release
HONG KONG, HK / ACCESS Newswire / July 24, 2026 / Seven days is what remains of LiberNovo's 2026 launch pricing. Across the EU and UK, Omni SE, Omni Pro, and the Maxis series hold their early bird prices until July 31, and the window closes there. The whole lineup is built around dynamic ergonomics: the support system links the neck support, backrest, armrests, and seat, so everything moves together as you shift, lean, and recline. The chair follows the movement; you get on with the work. A quick way to choose Omni SE: the simplest build in the lineup. No motor and no battery; you set the lumbar depth by hand and the automatic support does the rest. Solid dynamic ergonomics at the friendlier price. Better Comfort, Simplified. Omni Pro: the premium chair in the lineup. Motorized lumbar adjustment and the OmniStretch guided back stretch at the press of a button, plus Active Airflow ventilation built into the seat for long days and warm rooms, an aluminum base, and Danish Gabriel fabric.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom